category,datetime,headline,id,image,related,source,summary,url
company,1769458280,Will FDA’s Priority Review of At‑Home LEQEMBI IQLIK Dosing Change Biogen’s (BIIB) Narrative,138265013,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"Eisai and Biogen recently announced that the U.S. FDA has accepted for Priority Review a supplemental Biologics License Application for LEQEMBI IQLIK, a subcutaneous weekly autoinjector starting dose for early Alzheimer’s disease, with an FDA action date set for May 24, 2026. If approved, LEQEMBI IQLIK would be the first anti-amyloid Alzheimer’s therapy to offer at-home initiation and maintenance dosing, potentially reshaping how eligible patients begin and sustain treatment. We’ll now...",https://finnhub.io/api/news?id=20c5dee7f1ded4d0e05239d5b06addb749e57a7335e3114ee2a222e6a02ef770
company,1769425756,Biogen (BIIB) Valuation Check As Shares Trade Below Analyst Targets And Long Term Returns Stay Under Pressure,138260511,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,BIIB,Yahoo,"Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week, and a 3.1% decline over the past month. Over the past 3 months, Biogen has returned 15.1%, while year to date the stock is down 3.5%. Over longer horizons, the 1 year total return is 15.3%, compared with declines of 40.0% and 38.4% over the past 3 and 5 years, respectively. See our latest...",https://finnhub.io/api/news?id=408d44e0c1329b7396ec8860f4d074fa87504c34856f500ef90c8a764b519da4
